On this page you will find a repository of national and international guidance for health professionals on cancer management and COVID-19. The page has been updated to 09 July 2021 and is no longer being actively maintained. For advice specific to the health sector, please refer to the Department of Health and Aged Care's website.

[accordion]

Australia

Medical oncology guidelines, endorsed by Medical Oncology Group of Australia (MOGA) 
Practical considerations for treating patients with cancer in the COVID-19 pandemic
Date: 13-May-2020
Audience: Cancer clinicians
Purpose: Guidance for cancer clinicians, focusing on areas in medical oncology affected by COVID-19, including communication and the psychosocial impact of COVID-19 on cancer patients, as well as tumour specific considerations.

UK

National Health Service (NHS) England and NHS Improvement coronavirus
NHS England interim treatment options during the COVID-19 pandemic
Date: 30-Jun-2021
Audience: Health professionals including medical oncologists and radiation oncologists
Purpose: Interim treatment options in the management of cancer during the COVID-19 pandemic.

National Institute for Health and Care Excellence (NICE)
COVID-19 rapid guideline: delivery of systemic anticancer treatments
Date: 25-Mar-2021
Audience: Health and care practitioners
Purpose: Guidance to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

Blood cancer UK
Guidance for managing patients
Date: 03-Aug-2020
Audience: Health professionals
Purpose: Guidance for management of blood cancer patients during the COVID-19 pandemic.

USA

American Society of Clinical Oncology (ASCO)
Home Infusion of Anticancer Therapy
Date: 31-Jul-2020
Audience: Oncologists
Purpose: Guidance on home infusion of anticancer therapy during the COVID-19 pandemic.

Europe

Italian Association of Medical Oncology (AIOM)
COVID-19 Infection in Cancer Patients: What has been the Contribution of Associazione Italiana Oncologia Medica (AIOM) to Oncological Care Since the Beginning of the First Pandemic Wave?
Date: 19-Mar-2021
Audience: Medical oncologists
Purpose: Guidance on management of cancer patients during the COVID-19 pandemic.

German Society for Haematology and Medical Oncology (DGHO)
Evidence-based Management of COVID-19 in Cancer Patients – Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Date: 21-Sep-2020
Audience: Medical oncologists
Purpose: Guidance to provide evidence-based recommendations on prevention, diagnostics and treatment of cancer patients during the COVID-19 pandemic.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Breast cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of breast cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Colorectal cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of colorectal cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Gastro-esophageal tumors
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of gastro-oesophageal cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Hepatocellular carcinoma
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of hepatocellular carcinoma patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Pancreatic cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of pancreatic cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Urothelial cancer of the bladder
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of urothelial cancer of the bladder patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Renal cell cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of renal cell cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Prostate cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of prostate cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Cervical cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cervical cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Endometrial cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of endometrial cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Epithelial ovarian cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of epithelial ovarian cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphoma patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Hodgkin lymphoma
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of Hodgkin lymphoma patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Indolent B-NHL
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of indolent B-NHL patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Multiple myeloma
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of multiple myeloma patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Head and neck cancers
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of head and neck cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Lung cancer
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of lung cancer patients.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Melanoma
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of melanoma patients.

European Society for Medical Oncology (ESMO)
Palliative care prioritisation during the COVID-19 crisis
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising palliative care during the COVID-19 pandemic.

European Society for Medical Oncology (ESMO)
ESMO Management and Treatment adapted recommendations in the COVID-19 era: Primary brain tumours
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of primary brain tumour patients.

European Society for Medical Oncology (ESMO)
ESMO-Euracan Management and Treatment adapted recommendations in the COVID-19 era: Sarcomas
Date: 2020
Audience: Medical oncologists
Purpose: Guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of sarcoma patients.

European Society for Medical Oncology (ESMO)
Supportive care strategies during the COVID-19 crisis
Date: 2020
Audience: Medical oncologists
Purpose: Guidance on supportive care strategies during the COVID-19 pandemic.

Middle East

Lebanese Society of Medical Oncology (LSMO)
The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic
Date: 08-Apr-2020
Audience: Medical oncologists
Purpose: Rapid guidance notes for the management of patients with cancer in Lebanon.

[/accordion]